CA3115342A1 - Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases - Google Patents

Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases Download PDF

Info

Publication number
CA3115342A1
CA3115342A1 CA3115342A CA3115342A CA3115342A1 CA 3115342 A1 CA3115342 A1 CA 3115342A1 CA 3115342 A CA3115342 A CA 3115342A CA 3115342 A CA3115342 A CA 3115342A CA 3115342 A1 CA3115342 A1 CA 3115342A1
Authority
CA
Canada
Prior art keywords
compound
mice
donecopride
neurons
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3115342A
Other languages
English (en)
French (fr)
Inventor
Patrick Dallemagne
Christophe ROCHAIS
Sylvie Claeysen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Université de Caen Normandie
Institut National de la Santé et de la Recherche Médicale
University of Montpellier
Original Assignee
Centre National de la Recherche Scientifique
Université de Caen Normandie
Institut National de la Santé et de la Recherche Médicale
University of Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Université de Caen Normandie, Institut National de la Santé et de la Recherche Médicale, University of Montpellier filed Critical Centre National de la Recherche Scientifique
Publication of CA3115342A1 publication Critical patent/CA3115342A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3115342A 2018-09-28 2019-09-27 Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases Pending CA3115342A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306280.1A EP3628660A1 (en) 2018-09-28 2018-09-28 Donecopride and flucopride as neuroprotective agents in the treatment of neurodegenerative diseases
EP18306280.1 2018-09-28
PCT/EP2019/076229 WO2020065028A1 (en) 2018-09-28 2019-09-27 Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
CA3115342A1 true CA3115342A1 (en) 2020-04-02

Family

ID=63798921

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3115342A Pending CA3115342A1 (en) 2018-09-28 2019-09-27 Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases

Country Status (10)

Country Link
US (1) US20220031680A1 (cg-RX-API-DMAC7.html)
EP (2) EP3628660A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022511366A (cg-RX-API-DMAC7.html)
KR (1) KR20210098429A (cg-RX-API-DMAC7.html)
CN (1) CN113195452A (cg-RX-API-DMAC7.html)
AU (1) AU2019346024B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021005952A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115342A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202103070VA (cg-RX-API-DMAC7.html)
WO (1) WO2020065028A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3166146A1 (fr) 2024-09-12 2026-03-13 Université De Caen Normandie Sel de fumarate de 1-(4-amino-5-fluoro-2-méthoxyphényl)-3-[1-(cycloheptylméthyl)-4-pipéridinyl]propan-1-one –Composition pharmaceutique et utilisation associées
FR3166060A1 (fr) 2024-09-12 2026-03-13 Université De Caen Normandie Composition pharmaceutique formulée pour être administrée par voie intranasale et utilisable pour le traitement d’une maladie neurodégénérative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
FR2904113A1 (fr) 2006-07-21 2008-01-25 Exonhit Therapeutics S A Sa Procedes et outils pour la therapie de pathologies neurodegeneratives
CN102355902A (zh) * 2009-01-24 2012-02-15 植物药物公共有限公司 神经营养因子介导的病症的处理
FR3006686A1 (fr) 2013-06-05 2014-12-12 Univ Caen Composes inhibiteurs de l'acetylcholinesterase et agonistes des recepteurs serotoninergiques 5ht4, a effet promnesiant, leurs procedes de preparation et compositions pharmaceutiques les contenant
EA029951B1 (ru) * 2013-12-16 2018-06-29 Сувен Лайф Сайенсиз Лимитед Соединения индазола в качестве агонистов 5-ht-рецептора

Also Published As

Publication number Publication date
SG11202103070VA (en) 2021-04-29
KR20210098429A (ko) 2021-08-10
EP3856716A1 (en) 2021-08-04
AU2019346024B2 (en) 2024-07-18
US20220031680A1 (en) 2022-02-03
EP3628660A1 (en) 2020-04-01
CN113195452A (zh) 2021-07-30
JP2022511366A (ja) 2022-01-31
WO2020065028A1 (en) 2020-04-02
BR112021005952A2 (pt) 2021-06-29
AU2019346024A1 (en) 2021-04-29

Similar Documents

Publication Publication Date Title
Pierzynowska et al. Autophagy-dependent mechanism of genistein-mediated elimination of behavioral and biochemical defects in the rat model of sporadic Alzheimer's disease
Medrano-Jimenez et al. Malva parviflora extract ameliorates the deleterious effects of a high fat diet on the cognitive deficit in a mouse model of Alzheimer’s disease by restoring microglial function via a PPAR-γ-dependent mechanism
Corpas et al. SIRT1 overexpression in mouse hippocampus induces cognitive enhancement through proteostatic and neurotrophic mechanisms
Urano et al. Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid β‐induced neurite atrophy
Sun et al. Rehmannioside A attenuates cognitive deficits in rats with vascular dementia (VD) through suppressing oxidative stress, inflammation and apoptosis
Park et al. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation
Fine et al. Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice
Li et al. Early intervention attenuates synaptic plasticity impairment and neuroinflammation in 5xFAD mice
Easton et al. Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease
US20220119765A1 (en) Differentiation method of neural stem cells manufactured by direct cell conversion into astrocytes
US9603869B2 (en) Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
AU2019346024B2 (en) Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases
Cho et al. Phyllodulcin improves hippocampal long-term potentiation in 5XFAD mice
US20210038589A1 (en) Uses, compositions and methods
US20210338647A1 (en) Combination of Acetylcholinesterase Inhibitor and 5-HT4 Receptor Agonist As Neuroprotective Agent In the Treatment of Neurodegenerative Diseases
KR20200116054A (ko) 봉독 추출물을 유효성분으로 함유하는 신경염증 질환 예방 또는 치료용 조성물
WO2023078325A1 (zh) 一种含有依达拉奉右莰醇组合物在治疗认知障碍中的应用
RU2800802C2 (ru) Донекоприд как нейропротекторный агент при лечении нейродегенеративных заболеваний
US10618937B2 (en) Method of treating Alzheimer's disease
JP7249433B2 (ja) 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物
Lorke et al. α7-Nicotinic acetylcholine receptors and β-Amyloid peptides in Alzheimer’s disease
Liu et al. Blockage of IL-17 ameliorates Aβ-induced neurotoxicity and cognitive decline
US12605358B2 (en) Composition for preventing or treating nervous system diseases comprising compound that inhibits mTOR signaling pathway as active ingredient
Wang et al. Neuroprotective Effect of Hydroxysafflor Yellow A on an Alzheimer’s Disease (AD)-Like Mouse Model
Yang et al. Benzene, 1, 2, 4-Trimethoxy-5-(2-Methyl-1-Propen-1-yl) Attenuates D-galactose/AlCl3-induced Cognitive Impairment by Inhibiting Inflammation, Apoptosis, and improving Expression of Memory-Related Proteins

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240809

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20240809

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240916

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240916

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240916

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241017

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250331

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250806

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251113

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251208

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260330

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260708